Background. Few data relate interferon-γ-release-assay results in children to source case sputum status, the best predictor of infectiousness of tuberculosis (TB) patients. We evaluated the QuantiFERON-Gold-in-tube assay (QFT) and tuberculin skin test (TST) in children with different types of TB exposure. Methods. The TST and QFT were performed in referred TB-exposed children and adolescents who had not undergone prior TST screening (tested in parallel), and the QFT was performed in referred TST-positive individuals. Source case characteristics were obtained from referring public health units. We excluded children with known immunocompromising conditions and those known to have TB disease at the time of evaluation.
TST-positive individuals and use of the IGRA together with the TST in higher-risk cases [1, 14, 15] are recommended in the 2010 Canadian guidelines. In this study, we aimed to assess the tests in both situations.
METHODS

Study Setting and Population
The TB clinic at the Hospital for Sick Children (SickKids) in Toronto is the referral center used by public health units in the Greater Toronto Area for evaluation of childhood contacts of infectious cases of TB. The clinic also manages children with TB disease and evaluates children and adolescents who have undergone TST testing for a variety of reasons.
We used the QFT, according to Canadian guidelines [14, 15] , to evaluate patients referred to the SickKids' TB clinic between March 2008 and September 2010. Children were eligible for initial inclusion in the present study if they were younger than 18 years of age, were not known to be human immunodeficiency virus (HIV) positive, and had both a TST and a QFT performed with a TST-QFT interval of less than 60 days. Exclusion criteria included known primary or secondary immune compromised state (including HIV) or confirmed TB disease at the time of referral. Those in whom TB disease was detected after referral were included. The SickKids Research Ethics Board approved the study.
Patients were categorized into "tested in parallel" and "sequentially tested" groups according to the reason for referral and timing of TST and QFT testing. The testing in parallel group consisted of consecutive children referred by public health staff, because of contact with infectiouscase patients who had not undergone prereferral screening by the TST. To be included in this group, the TST had to have been performed after the date of referral to our clinic. To permit the inclusion of lower-risk contacts (who might not be seen for up to 3 weeks after referral), we included those whose TST-QFT interval was less than 20 days. The sequential testing group included all patients already known to have a positive TST at the time of referral, irrespective of the reason for testing.
Demographic, clinical, and bacteriological data were obtained using a standard clinic intake form. Tuberculosis contact was defined as exposure to a source case with culture-proven pulmonary or tracheal TB. Source case characteristics were obtained from the referring public health unit as part of routine care. Tuberculosis contact was classified according to place of contact and source case characteristics as follows: household smear-positive (HS+), household smear-negative (HS−), non-household smear-positive (NHS+), and non-household smearnegative (NHS−). For the purpose of analysis, those contacts who were not HS+ contacts were classified as lower-risk contacts. Country of birth was classified as low incidence if the reported TB incidence rate was <25/100 000 and high incidence if the TB rate was 25/100 000 [16] . Weight-for-age percentiles were determined using standard growth charts for North America [17] . Bacillus Calmette-Guerein vaccination was recorded from immunization records or deduced by the presence of a BCG scar.
TST and QFT Testing
The TST was performed and interpreted according to the Canadian TB guidelines [18] . Induration of 5 mm or greater was considered a positive test for contacts of infectious source cases, and induration 10 mm was considered positive for all other patients. For patients tested in parallel, TSTs were performed and read either by TB clinic staff or by nurses from the public health TB programs. Sequentially tested patients had TSTs performed and read by public health staff or other healthcare professionals. The QFT assay was performed using the QFT method according to manufacturer's instructions (Cellestis Ltd., Victoria, Australia) [19] . Blood was drawn by an onsite pediatric phlebotomy service. The tubes were shaken to coat the sides of the tubes and transported to an onsite laboratory within 2 hours. The tubes were then incubated for 16-24 hours, centrifuged, and the plasma was removed and frozen. Interferon-γ concentration in the plasma was assessed using an enzyme-linked immunosorbent assay reader. The test was considered positive when the value was 0.35 IU/mL (TB antigen minus nil). Results were considered indeterminate if the mitogen minus nil was <0.5 IU/mL or the nil was >8.0 IU/mL.
Statistical Analysis
Statistical analysis was performed using SAS version 9.3 (SAS Institute Inc., Cary, NC). Categorical data were compared by the Pearson's χ²-test (or Fisher's exact test, when expected cell sizes were smaller than 5). Continuous data were compared using the Student's t test. For the group tested in parallel, concordance between QFT-GIT and TST results was assessed using the kappa (κ) statistic. 
RESULTS
Two-hundred and thirty patients met the initial inclusion criteria. Twenty-one patients were excluded: 16 because of known immunocompromised state (none with HIV), 4 because of confirmed TB disease at the time of referral (all were TST-and QFT-positive), and 1 patient for whom data was incomplete (Figure 1 ). Ninety-two of the remaining patients were known to be TST-positive at the time of referral: 48 (52%) of these were contacts of infectious source cases, and 44 were tested for other reasons (17 because of adoption or immigration from a TB-endemic country; 10 prevolunteering at a healthcare facility; 16 because of work-up of symptoms that were judged not due to TB; and 1 before beginning immunosuppressive therapy for new onset uveitis). Of the 118 patients without prior TST testing, 14 were excluded because the TST-QFT interval was greater than 19 days, and 1 was excluded because of an indeterminate result due to low mitogen activity. The remaining 103 were included in the analysis of patients tested in parallel. Characteristics of the patient population are shown in Table l . Patients tested in parallel were significantly younger than those contacts referred because of positive TST's, consistent with public health policies of promptly referring younger contacts and clinic policies of prioritizing their evaluation. Because of long intervals between TST and QFT testing, none of the NHS− patients met the study criteria.
Test Performance
There were no phlebotomy failures. Five of the 230 patients tested during the study period had indeterminate QFT results due to low mitogen activity. Four of these 5 were excluded because of an immunocompromised state. The remaining indeterminate QFT result occurred in an 8-year-old contact with a negative TST. There were no indeterminate results due to high background activity. Forty-six (68%) of positive QFT values were >10 IU/mL, and 10 (15%) were between 1 and 10 IU/mL. Twelve positive values (17%) were <1.0 IU/mL but greater than the manufacturer's cut off of 0.35 IU/mL; <1.0 IU/mL values were found in 3 of the 4 TST-negative QFT-positive patients. For the 61 children younger than 5, 10 (83%) of the 12 positive tests had values >10 IU/mL and 2 (17%) were between 0 .36 and 1 IU/mL.
Patients Tested in Parallel
The median and mean interval between TST administration and QFT sampling of these 103 children was 0 days and 3.5 days, respectively (range, 0-19 days). Concordant TST-QFT results were observed in 74 (72%) children: 47 (46%) were concordant-negative and 27 (26%) were concordant-positive ( Table 2 For the 103 patients, overall agreement between the TST and QFT was fair to good (κ = 0.58; Table 2 ).
Agreement was excellent for those who had not received BCG (κ = 0.83: 16 concordant-positive, 1 TST-positive QFT-negative, and 1 QFT-positive TST-negative), and agreement was good but less strong for those born in low prevalence countries. Agreement was good for HS+ contacts but not for other contacts.
In univariate analysis, a positive TST was significantly associated with receipt of BCG vaccine (OR, 3.9; 95% CI, 1.7-9) and with household exposure to a smearpositive person (OR, 1.1; 95% CI, 1.1-5.7), but it was not associated with birth in a high incidence country (OR, 2.2; 95% CI, 0.9-5). In multiple logistic regression analysis, only BCG receipt retained significance (adjusted OR, 9.1; 95% CI, 1.7-48). A positive QFT was strongly associated with HS+ exposure both on univariate analysis (OR, 6.1; 95% CI, 2.3-20) and multiple logistic regression analysis (adjusted OR, 6.6; 95% CI, 2.2-20). There was no association between a positive QFT and BCG receipt (OR, 1.1; 95% CI, 0.7-5.2) or country of birth (OR, 0.6; 95% CI, 0.4-2.4).
Patients Tested Sequentially
Forty percent of these TST-positive children had a positive QFT (Tables l and 3 ; Figure 2 ). Referred TST-positive noncontacts were significantly more likely to have received BCG than referred TST-positive contacts (OR, 3.1; 95% CI, 1.3-7.30; P = .012). Household contact with a smearpositive source case was strongly associated with a positive QFT (P < .0001); 22 (78%) of the 28 HS+ contacts were QFT-positive compared with 7 (35%) of the 20 other contacts (OR, 6.8; 95% CI, 1.9-25; P < .003) and 8 (18%) of QuantiFERON Assay for Screening Children and Adolescents for TB 99 the noncontacts (OR, 15.5; 95% CI, 5-54; P < .0001) (Figure 1 ). Seven of the 8 patients with positive QFTs who had no known contact were born in countries with TB incidence > 100/100 000. All 8 QFT-positive noncontacts had resided in these countries for > 12 months: this duration was not significantly different from those QFT-negative patients born in higher incidence countries. None of the 18 noncontacts born in low incidence ( < 25/100 000 per year) countries had positive QFTs. There was no significant association between sex, age category, country of birth, BCG, or TST reaction size and a positive QFT. Among the 16 children younger than 5 in this group, there were 3 positive QFTs: 1 in the only HS+ contact <5 and 2 in adoptees.
Implications of Different Decision Rules for Patient Management
The implications of using the QFT as a confirmatory test in the 135 TST-positive individuals by different categories of contact status and age are shown in Table 4 . If a TST-positive QFT-negative result is interpreted as "no LTBI" (no latent TB infection), 82% of noncontacts, 64% of lower-risk contacts, and 22% of HS+ contacts would not be offered treatment. If we applied 2010 Canadian guidelines to our sample, testing with the QFT would avoid LTBI treatment in 43 (72%) of the 73 low-risk, TST-positive patients older than 5 who were not HS+ contacts. Current US guidelines, in which the IGRA is preferred over the TST as a test for asymptomatic children older than 5, would also potentially exclude an additional 27% (13) of the 48 HS+ contacts older than 5 [20] .
DISCUSSION
In this study, we used the performance of the QFT and TST in close contacts of smear-positive individuals as the standard by which to judge test performance in other situations. There are robust data indicating that the smear status is the single greatest predictor of the infectiousness of the source case and that proximity and duration of contact also affect transmission [8, 21] . Our data show a clear correlation between QFT, but not TST, results and the intensity of exposure, suggesting that, in these children and adolescents, the QFT, which was designed to have greater specificity than the TST, performs well.
This study included 151 patients with an identified source case, significantly more than in many pediatric studies of IGRAs in low burden countries. Nonetheless, it was a convenience sample, and although it showed some important differences, it was underpowered to show others. If we allowed for an alpha error of 0.05 and required 80% power, 105 in each group would have been needed to show a reduction from 35% to 17% in the proportion of QFT-positive patients between the serially tested low-risk contacts and noncontacts. A sample of 63 in each group would be needed to confirm a κ of 0.3 [22] .
In general, the test performed well at all ages. Indeterminate results occurred in 4 of 16 (25%) immunocompromised patients but in only 1 (0.5%) of 196 presumed immunocompetent patients. These rates are fairly similar to the overall rate of 1.4% in Lighter's [9] original study and of less than 1% in a population of contacts younger than 5 [23] . In contrast, an indeterminate rate of 25% was described in immunocompetent children in a tertiary hospital in the United Kingdom, and an 8% rate of indeterminate results was found in 2-to 4-year-old children in a large study from Greece [11, 13] . The reasons for this disparity are unclear. We were careful to exclude patients known to be immunocompromised. Our tests were performed in an onsite laboratory by a dedicated technician, and rapid incubation followed phlebotomy. Immediate incubation has been shown to reduce the incidence of indeterminate results [24] . There were no failures to obtain specimens, but blood was drawn in a dedicated outpatient phlebotomy facility at our tertiary pediatric hospital.
For the group tested in parallel, we allowed a maximum interval of 19 days between TST administration and QFT sampling. This method had the potential to produce falsepositive QFT results due to boosting by the TST [25] . However, this boosting phenomenon did not seem to be a factor in our patients. Of the 4 discordant TST-negative QFT-positive patients, 3 had sampling within 72 hours of TST administration.
In the contacts tested in parallel, we found fair overall agreement between the tests. The excellent agreement between those who had not received BCG (concordance, 93%; κ = 0.83) and poor agreement in those who were BCG-immunized (concordance, 63%; κ = 0.3) are similar to that of contacts (smear status unspecified) in the study by Critselis et al [11] , who found concordances of 94% (κ = 0.87) for BCG-nonimmunized and 53% (κ = 0.2) for BCG-immunized contacts. We found good test agreement in HS+ contacts (concordance, 83%; κ = 0.67) but poor agreement in exposures of lesser risk. The best agreement occurred in BCG nonimmunized household contacts (concordance, 96%; κ = 0.93). The majority of discordant results in our study were TST-positive and QFT-negative. This discordant TST-positive QFT-negative group had a significantly higher likelihood of being BCG-immunized and of having lower-risk contacts than the concordant-positive patients. The QFT showed good agreement with the TST in the 61 children younger than 5. In this group, the QFT but not the TST showed a good relationship to the degree of exposure, a similar finding to that of Critselis et al [11] ; however, our numbers are small. Current guidelines recommend the TST for this age group [20] . More data may permit revision of these guidelines, but given the risks of severe disease in this group [26] caution is still needed.
The addition of the QFT to the TST added little sensitivity for close contacts tested in parallel. If we assumed that all QFT results indicated true infection, only 4 (4%) more cases would be detected. Three of these results were lowlevel positives (<1 IU/mL), levels at which significant reversions and conversions have occurred on serial testing of adults [24] . For those patients who were already known to be TST-positive at the time of referral, the QFT again showed close correlation with the degree of contact. Thus, 82% of TST-positive noncontacts were QFT-negative compared with 22% of HS+ contacts.
To explore the implications of the use of this test, we applied different interpretations of current guidelines to our sample. If the QFT had been used as a confirmatory test for TST-positive patients older than 5 who had low risk or no contact, 43 of the 60 individuals (72%) would not be offered treatment. By contrast, if it was applied to all contacts of HS+ individuals, only 22% of treatment episodes would be averted.
Our findings may help guide the use of tests for LTBI in a low-burden setting, especially in locations where an IGRA is unavailable or difficult to obtain for logistic or financial reasons. Our data show that the TST remains a useful test for evaluating household contacts of smear-positive individuals. In this high-risk group, the QFT did not exclude many TST-positive patients from receiving LTBI treatment, and, importantly, QFT did not identify many additional infections compared with the TST alone. The TST also appeared to be very useful in contacts who had not received BCG. The QFT had its greatest role in lower-risk contacts and those evaluated for reasons other than contact, including immigration and adoption screening. This result was seen in both those who had not undergone prereferral TST screening and those known to be TST positive at the time of referral, suggesting that for this low-risk group, the QFT has utility either as a single test for LTBI or as a confirmatory test in TST-positive individuals. This approach is also in agreement with clinically important outcomes: in those at risk of severe forms of TB disease, such as young children, sensitivity is paramount, whereas in those at lower a priori risk of infection or of severe disease, specificity is more desirable. If the QFT is used for lower-risk individuals, many children and adolescents would not be offered treatment for LTBI. A recent paper from Montreal indicates that this method is a preferred approach for clinicians managing such patients [28] .
Many guidelines have recommended screening of children who immigrate from high-burden countries for LTBI [29] . Further investigation of the use of IGRAs in this group would be important, because their use is likely to substantially reduce the numbers offered LTBI treatment, thereby reducing the potential for toxicity and allowing a more targeted use of resources. Interferon-γ release assays would also likely be useful in evaluation of exposures in schools where (1) a high proportion of students have lived in endemic countries and have received BCG [30] and (2) in many Canadian First Nation communities where TB rates are low but BCG has, until recently, been administered to children [31] . It is clear that the evaluation of IGRAs in these settings should include longitudinal follow up of those TST-positive QFT-negative individuals to determine the rates of disease development in those who are not offered treatment.
This study has several limitations. For those tested in parallel, we allowed an interval of up to 19 days between the TST and QFT, which may have led to more positive QFTs, either due to boosting or because sufficient time had elapsed after exposure to produce an immune response. For the patients referred and known to be TST-positive, TSTs were planted and read by a range of healthcare professionals. Although this reflects the reality of testing in the community, the accuracy of planting and reading may be inferior to that done by dedicated TB clinic and public health personnel. We excluded all those who were known to be immunocompromised, and so we are unable to generalize our results to this group of individuals. The blood was drawn by an expert dedicated phlebotomy service in our tertiary pediatric institution. Obtaining accurate filling of the tubes in small children may be less achievable in other settings. The specimens were rapidly transferred to an onsite laboratory, which likely accounted for fewer indeterminate results than in some other studies. Nonetheless, our data suggest that the QFT assay has an important place in the evaluation of TB infection in children and adolescents in North America and other low-burden settings, and especially in those at an a priori lower risk of LTBI and those who have received the BCG vaccine. 
